

Welcome to the ARLG Newsletter! Here, you will receive important updates from ARLG regarding recent events, grants, publications, and the committees that help us work toward our mission: to prioritize, design, and execute clinical research that will impact the prevention, diagnosis, and treatment of infections caused by antibiotic resistant bacteria.

### Get Involved with ARLG

ARLG continuously accepts proposals for clinical studies designed to prevent, diagnose, treat, or eradicate antibiotic-resistant bacterial pathogens. We also award grants and fellowships to qualified investigators. If you are interested in getting involved with ARLG, apply now or contact us for more information.

Submit a Proposal

Contact Us

## News

### International Partnership Formed to Fight Antibacterial Resistance

The [Antibacterial Resistance Leadership Group \(ARLG\)](#), the [European Clinical Research Alliance on Infectious Diseases \(Eccraid\)](#), and the [ADVANCing Clinical Evidence in Infectious Diseases \(ADVANCE-ID\) Network](#) have united to combat antibacterial resistance globally. This alliance leverages ARLG's focus in the Americas, Eccraid's influence in Europe, and ADVANCE-ID's presence in the Asia Pacific. Through streamlined communication and shared resources, the groups aim to advance infectious disease clinical research.

Learn More

---

**GENO-STELLAR™ Registers Trademark**

ARLG is excited to announce the registration of the trademark for [GENO-STELLAR™](#), a groundbreaking tool that harnesses cutting-edge sequencing technologies and advanced analytical tools to provide comprehensive insights into antibacterial resistance mechanisms in clinical isolates.

GENO-STELLAR™, which stands for **GENO**mics, **S**equencing-based **T**yping, **E**pidemi**L**ogy, **L**inkage, and **A**ntimicrobial **R**esistance Tool, generates real-time reports with phylogenetic tree mapping and data comparisons, and offers invaluable predictive models for managing patients affected by multi-drug resistant bacteria.

[Learn More](#)

---

## ARLG Member, Eli Perencevich, MD, MS, Named Editor in Chief of JAMA Network Open

Eli Perencevich, MD, MS has been named editor in chief of [JAMA Network Open](#)! JAMA Network announced Dr. Perencevich's appointment on March 20; he will succeed the founding Editor in Chief, Frederick P. Rivara, MD, MPH on July 1, 2024.

Dr. Perencevich's work has focused on hospital-acquired infections by using mathematical models, large databases, and multicenter clinical trials to answer epidemiological and outcomes questions. He previously served on the ARLG Mentoring Committee from December 2019 through March 2024 helping to build the next generation of antibacterial resistance investigators.

[Learn More](#)

---

## ARLG Spotlight - Clinical Trials Specialist (CTS) Ivra Bunn is Retiring



Ivra Bunn, Clinical Trials Specialist at [Duke Clinical Research Institute](#) (DCRI), who has worked with ARLG since its inception 11 years ago, will be retiring this month. Her primary focus was providing services to help build the ARLG Network into what it is today. Some of her key contributions include independently organizing several meetings with the National Institutes of Health (NIH), network Principal Investigators (PIs), and external partners, creating the ARLG website, and launching applications for various ARLG awards available to the public. Ivra's retirement

plans include baking and going on her first trip abroad to the Dominican Republic in November. Please join us in thanking Ivra for her many years of dedicated service.

Read more

## ARLG Spotlight - Clinical Operations Project Leader and ARLG Laboratory Center Liaison Carol Hill is Retiring



Please help us thank Carol Hill, Clinical Operations Project Leader, and [ARLG Laboratory Center](#) Liaison, for all her enduring contributions to ARLG research. Carol began working on ARLG’s initial grant submission effort in 2013. Since then, her efforts have touched many critical aspects of ARLG Operations, from the Laboratory Center and the [SDMC](#), to the Clinical Operations Center. Carol played a foundational role in the development of the Laboratory Center’s [Biorepository – Strain Catalogue](#). Carol also has worked directly on multiple [ARLG studies](#), such as MDRO, SHREC, SCENE, DOTS, FAST, and GENO-STELLAR. We wish Carol a well-deserved relaxing retirement!

Read more

## Events

### ARLG Grand Rounds

| Date            | Title   | Presenter(s)  |
|-----------------|---|---|
| January 5, 2024 | <a href="#">Brave new world: promise and perils of generative AI for ID professionals</a> | Ilan Schwartz, MD<br>Associate Professor of Medicine, Division of Infectious Diseases, Duke University School of Medicine |

# ARLG at ECCMID 2024

The 34<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) is coming up on April 27-30, 2024 in Barcelona, Spain! This annual conference is the largest gathering in Europe focused on research related to clinical microbiology and infection.

Catch the following presentations by ARLG Network colleagues and be among the first to learn the results of these ARLG studies!

## Poster/Oral Presentations

**Date:** 29 April 2024

**Number:** 09258

**Time:** 8:30 - 9:30 am

**Title:**

Dalbavancin is non-inferior to standard of care therapy for complicated *Staphylococcus aureus* bacteremia (SAB)

**Location:**

Hall E/ OS164

Late Breakers: Clinical Trials:

Antimicrobial Resistant Bacteria

**Study:** DOTS

**Presenting Author:** N. Turner

**Authors:**

Nicholas A. Turner, Toshimitsu Hamasaki, Scott Evans, Sarah B. Doernberg, Thomas P. Lodise, Heather King, Varduhi Ghazaryan, Sara E. Cosgrove, Timothy C. Jenkins, Catherine Liu Shrabani, Sharma Smitha Zaharoff, Lana Wahid, Paul Cook, Issam Raad, Ray Hachem, Anne-Marie Chaftari, Matthew Sims, Carmen DeMarco, Loren G. Miller, Matthew W. McCarthy, Caryn G. Morse, Chris Lucasti, Graeme Forrest, Kartikeya, Cherabuddi, Christopher Polk, Tasaduq Fazili, Mark E. Rupp, George R. Thompson, Kami Kim, Luke Strnad, Amanda E. Schnee, James A. McKinnell, Mayur Ramesh, Fernanda P. Silveira, Todd P. McCarty, Todd C. Lee, Emily G. McDonald, Kristopher Paolino, Katie Wiegand Meng, Alison Wall, Todd Riccobene, Rinal Patel, Urania Rappo, Henry F. Chambers, Vance G. Fowler, Jr., Thomas L. Holland, On behalf of the Antibacterial Resistance Leadership Group

---

**Date:** 29 April 2024

**Number:** P1829

**Time:** 12:00 - 13:30 pm

**Title:**

Black females hospitalised in the United States have worse outcomes after carbapenem-resistant Enterobacterales (CRE) bloodstream infection (BSI)

**Location:** Poster Area

**Study:** REPROCESS

**Presenting Author:** F. Ruffin

**Authors:**

Felicia Ruffin, Lizhao Ge, Lauren Komarow, Melinda Pettigrew, Vance G. Fowler, Jr., David Van Duin

---

**Date:** 29 April 2024

**Number:** P1812

**Time:** 12:00 - 13:30 pm

**Location:** Poster Area

**Title:**

Resistance to novel  $\beta$ -lactam/ $\beta$ -lactamase inhibitors among carbapenem-resistant *Pseudomonas aeruginosa* and clinical implications in the Prospective Observational Pseudomonas (POP) study

**Study:** POP-MDRO

**Presenting Author:** L. Gottesdiener

**Authors:**

Lee Gottesdiener, Yixuan Li, Kerry Greenwood-Quaintance, Lauren Komarow, Cesar Arias, Eric Cober, Erica Herc, Thamer Alenazi, Keith Kaye, W. Charles Huskins, Jairo Figueroa, Samuel Vilchez, Bettina Fries, Marcel Leroi, Todd McCarty, Maria Rioseco, Jose Munita, Martin Stryjewski, Jinnethe Reyes, Liang Chen, Barry Kreiswirth, Carol Hill, Keri Baum, Maria Virginia Villegas, David Paterson, Robert Bonomo, Henry Chambers, Vance Fowler, Robin Patel, Yohei Doi, David Van Duin, Michael Satlin

[Learn more](#)



## Study Milestones

View recent ARLG study updates.

|                        |   |               |
|------------------------|---|---------------|
| <b>DOTS</b>            | Dalbavancin as an Option for Treatment of <i>S.aureus</i> Bacteremia  | Data Analysis |
| <b>FAST</b>            | Fast Antibiotic Susceptibility Testing for gram-negative bacteremia   | Enrolling     |
| <b>MASTERMIND-RING</b> | <b>MASTER</b> protocol for evaluating Multiple Infection Diagnostics-Resistant <i>Neisseria Gonorrhoeae</i> | Start-up      |
| <b>PDP</b>             | Pneumonia Direct Pilot  | Enrolling     |
| <b>RADICAL-3</b>       | Rapid Diagnostic in Categorizing Acute Lung Infections  | Study Design  |
| <b>OPTIMIZE-GNI</b>    | <b>OPTIMIZ</b> ation of Beta-lactam Dosing in Critically-Ill Patients with Suspected or                     | Start-up      |

IMPROVE-LRTI

Integrated Metagenomic  
PROfiling to adVance LRTI  
diagnosis and stewardship  
in lung transplant

Study Design

Go to the ARLG Studies page for more milestones and updates!

Learn More



## New Publications

View the following recent ARLG publications.

Fisher M, Komarow L, Dai W, Patel G, Revolinski S, Huskins WC, van Duin D, Banerjee R, Fries BC; Carbapenem-Resistant Enterobacterales Infection in Children at 18 US Hospitals: Clinical and Molecular Epidemiology from a Prospective Multicenter Cohort Study; *Open Forum Infect Dis.* 2024 Jan 8;11(2):ofad688. doi: 10.1093/ofid/ofad688.

Mackow NA, van Duin D; Reviewing Novel Treatment Options for Carbapenem-resistant Enterobacterales; *Expert Rev Anti Infect Ther.* 2024 Jan-Jun;22(1-3):71-85. doi: 10.1080/14787210.2024.2303028.

Pelletiers W, Kwon J, Galloway Peña J, van Duin D, Ledbetter L, Baum K, Ruffin F, Knisely J, Bizzell E, Fowler, Jr. VG, Chambers H, Pettigrew MM on behalf of the Antibacterial Resistance Leadership Group; Participant Diversity in United States Randomized Controlled Trials of Antibacterials for *Staphylococcus aureus* Infections, 2000-2021; *Clin Infect Dis.* 2024 Feb 2:ciae049. doi: 10.1093/cid/ciae049. Online ahead of print.

Minggui Wang, Lizabeth Ge, Liang Chen, Lauren Komarow, Blake Hanson, Jinneth Reyes, Eric Cober, Thamer Alenazi, Zhiyong Zong, Qing Xie, Zhengyin Liu, Lanjuan Li, Yunsong Yu, Hainv Gao, Souha S Kanj, Jairo Figueroa, Erica Herc, Ezequiel Cordova, Gregory Weston, Paul Ananth Tambyah, Julia Garcia-Diaz, Keith S Kaye, Sorabh Dhar, Jose M Munita, Robert A Salata, Samuel Vilchez, Martin E Stryjewski, Maria Virginia Villegas Botero, Alina Iovleva, Scott R Evans, Keri Baum, Carol Hill, Barry N Kreiswirth, Robin Patel, David L Paterson, Cesar A Arias, Robert A Bonomo, Henry F Chambers, Vance G Fowler, Michael J Satlin, David van Duin, Yohei Doi, Multi-Drug Resistant Organism Network Investigators, Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant *Acinetobacter baumannii* Among Patients From Different Global Regions, *Clinical Infectious Diseases*, Volume 78, Issue 2, 15 February 2024, Pages 248–258, doi:10.1093/cid/ciad556.

Howard-Anderson J, Hamasaki T, Dai W, Collyar D, Rubin D, Nambiar S, Kinamon T, Leister-Tebbe H, Hill C, Geres H, Holland TL, Doernberg SB, Chambers HF, Fowler Jr. VG, Evans SR, Boucher HW; Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator Associated Bacterial Pneumonia; *Clin*

Infect Dis. 2024 Feb 17;78(2):259-268. doi: 10.1093/cid/ciad576.

**Valentine-King M, Hansen MA, Zoorob R, Schlueter M, Matas JL, Willis SE, Danek LCK, Muldrew K, Zare M, Hudson F, Atmar RL, Chou A, Trautner B, Grigoryan L; Determining a Urinary-Specific Antibiogram and Risk Factors of Resistance to Trimethoprim-Sulfamethoxazole, Ciprofloxacin, and Multidrug Resistance among Enterobacterales in Primary Care; J Antimicrob Chemother. 2024 Mar 1;79(3):559-563. doi: 10.1093/jac/dkae004.**

Iovleva A, McElheny CL, Fowler EL, Hill C, Baum K, Fowler, Jr. VG, Chambers HF, Greenwood-Quaintance KE, Patel R, van Duin D, Bonomo RA, Doi Y; In Vitro Activity of Sulbactam-Durlobactam Against Colistin-Resistant and/or Cefiderocol-Non-Susceptible, Carbapenem-Resistant Acinetobacter Baumannii Collected in U.S. Hospitals; Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0125823. doi: 10.1128/aac.01258-23.

**Kinamon T, Waack U, Needles M, Rubin D, Collyar D, Doernberg SB, Evans S, Hamasaki T, Holland TL, Howard-Anderson J, Chambers H, Fowler, Jr. VG, Nambiar S, Kim P, Boucher HW, Gopinath R; Exploration of a Potential DOOR Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs; Clin Infect Dis. Published online March 25, 2024. doi:10.1093/cid/ciae163**

Franzone JP, Mackow N, van Duin D; Current Treatment Options for Pneumonia Caused by Carbapenem-Resistant Acinetobacter baumannii; Curr Opin Infect Dis. 2024 Apr 1;37(2):137-143. doi: 10.1097/QCO.0000000000001001.

Duke Clinical Research Institute | 300 West Morgan Street, Suite 800, Durham, NC 27701

[Unsubscribe dcri-emailtools@duke.edu](mailto:dcri-emailtools@duke.edu)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by arlg\_network@dm.duke.edu powered by



Try email marketing for free today!